Elbasvir/grazoprevir (EBR/GZR) is an all-oral direct-acting antiviral agent (DAA) with high sustained virologic response (SVR) in clinical trials. This study's primary objective was to evaluate effectiveness of EBR/GZR among HCV-infected patients in a real-world clinical setting. We conducted a nationwide retrospective observational cohort study of HCV-infected patients in the US Department of Veterans Affairs (VA) using the VA Corporate Data Warehouse. The study population included patients with positive HCV RNA who initiated EBR/GZR from February 1 to August 1, 2016. We calculated the 95% confidence interval for binomial proportions for SVR overall and by demographic subgroups. Clinical and demographic characteristics were also evaluated. We included 2436 patients in the study cohort. Most were male (96.5%), African American (57.5%), with mean age of 63.5 (SD = 5.9) and 95.4% infected with genotype (GT) 1 [GT1a (34.7%), GT1b (58.6%)]. Other comorbidities included diabetes (53.2%), depression (57.2%) and HIV (3.0%). More than 50% had history of drug or alcohol abuse (53.9% and 60.5%, respectively). 33.2% of the cohort had cirrhosis. A total of 95.6% (2,328/2,436; 95% CI: 94.7%-96.4%) achieved SVR.
| INTRODUC TI ON
Chronic hepatitis C virus (HCV) infection affects 1.3% of the US population 1, 2 and is the leading cause of cirrhosis, hepatocellular cancer and death from liver disease in the US. 3 The new all-oral direct-acting antivirals (DAAs) result in SVR in an unprecedented >90% of patients in clinical trials. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and those with inherited blood disorders with low adverse-event rates. [13] [14] [15] Randomized controlled trials of EBR/GZR reported high efficacy for the treatment-naïve and treatment-experienced patients including special populations. In integrated analyses of EBR/GZR trials among GT 1 patients with and without cirrhosis, SVR rates were greater than 95% in all patient subgroups. 16, 17 Among patients infected with HCV GT 1 and stage 4-5 CKD, the phase 3 clinical trial of EBR/GZR showed that the SVR rates were 99%
with low adverse-event rates. 18 However, the chasm between efficacy (in clinical trials) and effectiveness (in clinical practice)
persists in the DAA era. The few data that are available from real-world experience suggest that SVR rates with all-oral DAAs may be lower than those reported in clinical trials (~75%-80% vs >90%, respectively). [19] [20] [21] [22] In contrast, other data suggest that the effectiveness of DAAs may be comparable to efficacy observed in clinical trials. 23, 24 Previous real-world studies and clinical trials have also reported factors associated with lower response rates including nonadherence, African American race, 4, 25, 26 having cirrhosis, 22, 24, 26 and male gender.
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To our knowledge, there have been no published reports examining the effectiveness of EBR/GZR regimens in real-world clinical practice. Therefore, the objective of the study was to evaluate effectiveness among HCV-infected patients treated with EBR/GZR in a real-world clinical setting in the US using data from the US Department of Veterans Affairs (VA) healthcare system.
| MATERIAL S AND ME THODS
This was a retrospective analysis of administrative and clinical data using the VA Corporate Data Warehouse (CDW) which is a national data repository of VA electronic medical records including those of almost 9 million veterans. The CDW includes data from pharmacy, laboratory, inpatient and outpatient encounters by ICD-9/10 diagnosis codes, as well as vital status from October 1, 1999 through present day. The VA is the largest single provider of HCV care in the US due to the fact that veterans are 3 times more likely to be infected with HCV.
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| Study populations and definitions
The study cohort included subjects who initiated EBR/GZR treat- 
| Outcomes measures and demographic and clinical variables
Sustained virologic response was defined as HCV RNA below the limit of quantification performed at least 12 weeks after the end of treatment. If HCV RNA data at ≥12 weeks were not available, SVR was defined based on HCV RNA testing available from week 4 to 12 weeks after the end of treatment to account for variability of clinic visits and availability of laboratory data in clinical practice. This definition of SVR has been used in other similar database studies 25, 29 and SVR4 has been shown to be highly concordant with SVR12.
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The end of treatment was calculated from the last day covered by the medication dispensed by totaling the number of days supply. 
| Data analysis
Descriptive statistics were used to describe demographic and clinical characteristics such as HCV GT, baseline HCV viral load, HIV 
| RE SULTS
During the study period, we identified 2985 chronic HCV-infected patients who initiated EBR/GZR regimens. After applying study inclusion and exclusion criteria, 2436 patients were included in the EP cohort as a primary study population. When excluding those who did not complete treatment regimen (7.3%, n = 179), the PP cohort included 2257 patients ( Figure 1 ).
| Cohort characteristics overall and by treatment regimen
Baseline demographic and clinical characteristics of EP by EBR/ GZR treatment regimen are shown in Table 1 . Of 2436 patients in the evaluable population, 2246 (92.2%) were prescribed EBR/GZR without RBV, followed by EBR/GZR+RBV (6.4%, n = 156) and EBR/ GZR + SOFs ± RBV (1.4%, n = 34 
| SVR rates overall and by subgroups
In the EP cohort (n = 2436), 95.6% (95%CI: 94.7%-96.4%) of veterans prescribed EBR/GZR regimens achieved SVR (Table 2) . When including only patients who completed at least 11 weeks of treatment, the SVR rate in the PP cohort was 97.0% (2190/2257; 95%CI:
96.3%-97.7%). 
| SVR rates among GT1-and GT4 HCV-infected patients by treatment regimen
In the subgroup analysis that excluded patients with prior treatment experience with all-oral DAAs or those who had decompensated cirrhosis which were not indicated in the US FDA labelling for EBR/ GZR, the majority of patients were treated with EBR/GZR without RBV (94% in GT1 and 96.6% in GT4) ( 
| D ISCUSS I ON
This study evaluated the real-world effectiveness of EBR/GZR in the first 6 months after approval in the large VA national healthcare system. Our study showed that EBR/GZR was highly effective, with an SVR of 95.6% overall and 97% in patients who completed a full course of treatment. SVR rates were high across patient subgroups 
Evaluable population (EP) (n = 2436)
Per protocol population (PP) (n = 2257) regardless of gender, race/ethnicity, presence of cirrhosis, renal impairment or HIV co-infection. To our knowledge, this is the largest real-world effectiveness study of EBR/GZR of 2436 patients.
TA B L E 1 Baseline and clinical characteristics among chronic HCV-infected patients treated with EBR/GZR in the evaluable population

TA B L E 2 Sustained virologic response (SVR) in patients treated with EBR/GZR ± RBV (all genotypes) by baseline characteristics in the evaluable population (N = 2436)
Randomized controlled trials demonstrated high SVR rates for EBR/ GZR ranging from 90% to 100%. [13] [14] [15] Compared to the integrated analysis of 6 clinical trials among patients with HCV GT 1, 4 and 6 infection, 36 HCV patients in this study were older, had a higher prevalence of comorbidities, and had a higher percent of treatment were observed among all these findings. While the other 3 studies reported negative impact on response rates in patients with cirrhosis, patients with cirrhosis in our study did not have an attributably lower SVR than patients without cirrhosis as the SVR rates were 95.6% in both groups. One-third of patients treated had CKD stage 3-5, which was higher than those treated with other all-oral DAAs observed in literature (ie 6.9%-27.3%). 37, 38 Our results suggest that HCV can be effectively treated among these highly vulnerable patients with CKD or in the high-risk population. Finally, although the US FDA labelling of EBR/GZR is not indicated for those with prior exposure to NS5A DAAs or those with decompensated cirrhosis, about 5% had prior use of NS5A and 14% had decompensated cirrhosis. Our finding reported slightly lower SVR rates than overall in patients with prior exposure to LDV/SOF or PrOD (ie 82.9%-88.6%) during the first 6 months after the approval.
Our study has several strengths. First, we used data from the nationwide VA database, which is the largest integrated healthcare data source for patients with HCV, including those who are racially and clinically diverse. Second, missing data is relatively low because the VA healthcare system has an established electronic medical record system as well as a robust pharmacy benefits management system including prescriptions data across all VA facilities. However, this study is subject to certain limitations. The VA population may not be generalizable to the entire US population due to the potential for differing demographic risk factors. Misclassification bias may exist, as diagnoses and co-morbidities were identified through ICD-9/10 codes. Sample sizes were low for some subgroups (ie EBR/ GZR+RBV for 16 weeks) and larger studies are needed to determine more robust results. Additionally, some laboratory data, including data on the presence of baseline NS5A resistance-associated substitutions (RAS), was not available at the time of this analysis. Adverse events data was also not available in this study. Future studies are needed to examine the impact of RAS and RBV on real-world effectiveness of EBR/GZR.
In conclusion, EBR/GZR regimens were highly effective, with an overall SVR of 96% and 97% in the EP and PP cohorts, respectively.
SVR rates were high across patient subgroups regardless of gender, race/ethnicity, presence of cirrhosis, history of drug or alcohol abuse, renal impairment or HIV co-infection. This studied provides important data regarding the effectiveness of EBR/GZR in a large clinical setting.
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